Sıdıka Gülkan Özkan1, Hatice Yazısız2, Ahmet Behlül1, Yüksel Aslı Gökbelen1, Fatih Borlu1, Veli Yazısız3. 1. Department of Internal Medicine, Şişli Etfal Training and Research Hospital, İstanbul, Turkey. 2. Department of Microbiology, Akdeniz University School of Medicine, Antalya, Turkey. 3. Department of Internal Medicine, Şişli Etfal Training and Research Hospital, İstanbul, Turkey; Division of Rheumatology, Department of Internal Medicine, Akdeniz University School of Medicine, Antalya, Turkey.
Abstract
OBJECTIVE: The aim of this study was to identify the prevalence of metabolic syndrome (MetS) and degree of cardiovascular disease (CVD) risk in patients with psoriatic arthritis (PsA). MATERIAL AND METHODS: We performed a cross-sectional study on 102 adult patients with PsA and a control group of 102 patients with rheumatoid arthritis (RA). MetS was diagnosed according to the National Cholesterol Education Program Adult Treatment Panel III (NCEP-ATP III) and International Diabetes Federation (IDF) criteria. The Framingham risk scores of 10-year risk of CVDs and coronary heart disease (CHD) were also calculated. RESULTS: The prevalence of MetS was higher in patients with PsA than in those with RA, according to the NCEP-ATP III (40.6% vs. 24.7%, respectively; p=0.019) and IDF (46.8% vs. 27.9%, respectively; p=0.05) criteria. The prevalence of MetS was higher in female patients with PsA (p=0.009) than in male patients. A significantly increased prevalence of hypertriglyceridemia was determined in patients with PsA (p=0.019). No significant difference existed between the two groups with respect to 10-year CVD (p=0.333) and CHD (p=0.798) risks. Additionally, there were no significant differences between the clinical subtypes of PsA with regard to MetS (p=0.229). CONCLUSION: MetS prevalence increased in patients with PsA compared with those with RA, whereas the risks were similar for CVDs and CHD. For this reason, optimal protection measures should be taken and guidelines should be applied to achieve adequate metabolic control in patients with PsA.
OBJECTIVE: The aim of this study was to identify the prevalence of metabolic syndrome (MetS) and degree of cardiovascular disease (CVD) risk in patients with psoriatic arthritis (PsA). MATERIAL AND METHODS: We performed a cross-sectional study on 102 adult patients with PsA and a control group of 102 patients with rheumatoid arthritis (RA). MetS was diagnosed according to the National Cholesterol Education Program Adult Treatment Panel III (NCEP-ATP III) and International Diabetes Federation (IDF) criteria. The Framingham risk scores of 10-year risk of CVDs and coronary heart disease (CHD) were also calculated. RESULTS: The prevalence of MetS was higher in patients with PsA than in those with RA, according to the NCEP-ATP III (40.6% vs. 24.7%, respectively; p=0.019) and IDF (46.8% vs. 27.9%, respectively; p=0.05) criteria. The prevalence of MetS was higher in female patients with PsA (p=0.009) than in male patients. A significantly increased prevalence of hypertriglyceridemia was determined in patients with PsA (p=0.019). No significant difference existed between the two groups with respect to 10-year CVD (p=0.333) and CHD (p=0.798) risks. Additionally, there were no significant differences between the clinical subtypes of PsA with regard to MetS (p=0.229). CONCLUSION: MetS prevalence increased in patients with PsA compared with those with RA, whereas the risks were similar for CVDs and CHD. For this reason, optimal protection measures should be taken and guidelines should be applied to achieve adequate metabolic control in patients with PsA.
Authors: Daniel Aletaha; Tuhina Neogi; Alan J Silman; Julia Funovits; David T Felson; Clifton O Bingham; Neal S Birnbaum; Gerd R Burmester; Vivian P Bykerk; Marc D Cohen; Bernard Combe; Karen H Costenbader; Maxime Dougados; Paul Emery; Gianfranco Ferraccioli; Johanna M W Hazes; Kathryn Hobbs; Tom W J Huizinga; Arthur Kavanaugh; Jonathan Kay; Tore K Kvien; Timothy Laing; Philip Mease; Henri A Ménard; Larry W Moreland; Raymond L Naden; Theodore Pincus; Josef S Smolen; Ewa Stanislawska-Biernat; Deborah Symmons; Paul P Tak; Katherine S Upchurch; Jirí Vencovsky; Frederick Wolfe; Gillian Hawker Journal: Ann Rheum Dis Date: 2010-09 Impact factor: 19.103
Authors: L-S Tam; B Tomlinson; T T-W Chu; M Li; Y-Y Leung; L-W Kwok; T K Li; T Yu; Y-E Zhu; K-C Wong; E W-L Kun; E K Li Journal: Rheumatology (Oxford) Date: 2008-04-09 Impact factor: 7.580
Authors: Lai-Shan Tam; Qing Shang; Edmund K Li; Brian Tomlinson; Tanya T W Chu; Martin Li; Ying-Ying Leung; Lai-Wa Kwok; Kong-Chiu Wong; Tena K Li; Tracey Yu; Tracy Y Zhu; Emily W Kun; Gabriel W Yip; Cheuk-Man Yu Journal: Arthritis Rheum Date: 2008-09-15
Authors: Rebecca Haberman; Lourdes M Perez-Chada; Joseph F Merola; Jose Scher; Alexis Ogdie; Soumya M Reddy Journal: Curr Rheumatol Rep Date: 2018-10-26 Impact factor: 4.592
Authors: A Schmidt; A M Glimm; I K Haugen; P Hoff; G Schmittat; G R Burmester; J Klotsche; S Ohrndorf Journal: Arthritis Res Ther Date: 2020-08-18 Impact factor: 5.156